Overview

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2107 with Keytruda® marketed in China and the United States in healthy male volunteers. Participants will receive a single injection of QL2107/ Keytruda® （China）/Keytruda® （US）.Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the three groups.

Phase:

Phase 1

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

Pembrolizumab